Gynecologic Oncology

Article	Citations
Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990–2019	106
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)	103
Outcomes of enhanced recovery after surgery (ERAS) in gynecologic oncology – A systematic review and meta-analysis.	90
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer	87
Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification	78
Stromal POSTN induced by TGF-β1 facilitates the migration and invasion of ovarian cancer	73
Vulvar cancer subclassification by HPV and p53 status results in three clinically distinct subtypes	68
Clinical assays for assessment of homologous recombination DNA repair deficiency	67
Uterine serous carcinoma	59
Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer	59
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer	58
Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity	55
Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment	54
Exosomal microRNAs and exosomal long non-coding RNAs in gynecologic cancers	53
Validation of American College of Radiology Ovarian-Adnexal Reporting and Data System Ultrasound (O-RADS US): Analysis on 1054 adnexal masses	53
Recurrence rate after loop electrosurgical excision procedure (LEEP) and laser Conization: A 5-year follow-up study	52
Histopathological characterization of ProMisE molecular groups of endometrial cancer	51
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial	51
FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival	51
Gynecologic cancer in pregnancy	50
Clear cell carcinoma of the ovary: Epidemiology, pathological and biological features, treatment options and clinical outcomes	49
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer	49
Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations	47
Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: Results from the phase 3 javelin ovarian 100 trial	47
Artificial intelligence-assisted cytology for detection of cervical intraepithelial neoplasia or invasive cancer: A multicenter, clinical-based, observational study	47

Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer	46
Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial	46
Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma	44
Should endometrial biopsy under direct hysteroscopic visualization using the grasp technique become the new gold standard for the preoperative evaluation of the patient with endometrial cancer?	44
Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study	43
An integrated molecular profile of endometrioid ovarian cancer	43
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial	43
Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: A multi-center study	43
Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study	42
Harnessing natural killer cells for the treatment of ovarian cancer	42
Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract	42
Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study	42
Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss	41
Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial	41
Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer	40
Achieving universal genetic assessment for women with ovarian cancer: Are we there yet? A systematic review and meta-analysis	40
The current landscape of molecular profiling in the treatment of epithelial ovarian cancer	40
When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic	39
Immunotherapy for platinum-resistant ovarian cancer	38
Prognostic value of myometrial invasion and TCGA groups of endometrial carcinoma	38
Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer	38
Homologous recombination deficiency real-time clinical assays, ready or not?	38
Lymphovascular space invasion in endometrial carcinoma: A prognostic factor independent from molecular signature	37
Non-coding RNAs related to angiogenesis in gynecological cancer	36
Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis	36
Natural language processing with machine learning to predict outcomes after ovarian cancer surgery	35
The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on respo	35
Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer	35
Incidence and mortality of ovarian cancer at the global, regional, and national levels, 1990–2017	35
Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: An NRG oncology/gynecologic oncology group study	35
Gynecologic oncology care during the COVID-19 pandemic at three affiliated New York City hospitals	34
A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2/3 (CIN2/3)	34
Ten-year outcomes following laparoscopic and open abdominal radical hysterectomy for “low-risk” early-stage cervical cancer: A propensity-score based analysis	34
High-risk HPV-positive and -negative high-grade cervical dysplasia: Analysis of 5-year outcomes	34
Cancer patients affected by COVID-19: Experience from Milan, Lombardy	33
The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration	33
Predictors of recurrence following laparoscopic radical hysterectomy for early-stage cervical cancer: A multi-institutional study	32
Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma	32
Naples prognostic score is an independent prognostic factor in patients with operable endometrial cancer: Results from a retrospective cohort study	32
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer	31
Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor	31
High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer	31
Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends	31
Sentinel node mapping vs. sentinel node mapping plus back-up lymphadenectomy in high-risk endometrial cancer patients: Results from a multi-institutional study	31
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review	30
Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement	30
Survival outcomes in endometrial cancer patients having lymphadenectomy, sentinel node mapping followed by lymphadectomy and sentinel node mapping alone: Long-term results of a propensity-matched anal	30
GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function	30
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL)	30
CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes	29

Preoperative frailty assessment in patients undergoing gynecologic oncology surgery: A systematic review	29
Enhanced recovery after surgery (ERAS®) society guidelines for gynecologic oncology: Addressing implementation challenges - 2023 update	29
The feature of cervical microbiota associated with the progression of cervical cancer among reproductive females	29
Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of	29
Ovarian cancer symptoms, routes to diagnosis and survival – Population cohort study in the ‘no screen’ arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)	29
Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors	29
Clinical and analytical evaluation of the RealTime High Risk HPV assay in Colli-Pee collected first-void urine using the VALHUDES protocol	28
Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?	28
Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer	28
Manipulating the Wnt/β-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy	28
Outcomes and patient perspectives following implementation of tiered opioid prescription guidelines in gynecologic surgery	28
Extramammary Paget disease of the vulva: Management and prognosis	28
Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: An international multi-institutional study	28
The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance	28
Rapid dissemination of practice-changing information: A longitudinal analysis of real-world rates of minimally invasive radical hysterectomy before and after presentation of the LACC trial	27
Are ethnic and racial minority women less likely to participate in clinical trials?	27
Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer	27
[18F]FDG-PET or PET/CT in the evaluation of pelvic and para-aortic lymph nodes in patients with locally advanced cervical cancer: A systematic review of the literature	27
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial	27
A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanc	27
Ultrasound detection of endometrial cancer in women with postmenopausal bleeding: Systematic review and meta-analysis	27
Updates on conservative management of endometrial cancer in patients younger than 45 years	27
Common medications and survival in women with ovarian cancer: A systematic review and meta-analysis	27
Radiation therapy for gynecologic malignancies during the COVID-19 pandemic: International expert consensus recommendations	27
Comparison between robot-assisted radical hysterectomy and abdominal radical hysterectomy for cervical cancer: A multicentre retrospective study	27
Quantitative proteomic analysis identifies novel regulators of methotrexate resistance in choriocarcinoma	26
Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer	26
Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis	26
Racial disparities in high-risk uterine cancer histologic subtypes: A United States Cancer Statistics study	26
Physical activity and exercise in women with ovarian cancer: A systematic review	26
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian can	26
Management and outcomes of primary vaginal Cancer	26
Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification	26
Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis	26
Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study	26
Adjusting to the new reality: Evaluation of early practice pattern adaptations to the COVID-19 pandemic	25
Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D	25
Modified fragility index and surgical complexity score are able to predict postoperative morbidity and mortality after cytoreductive surgery for advanced ovarian cancer	25
Efficacy and safety of niraparib as maintenance treatment in patients with newly diagnosed advanced ovarian cancer using an individualized starting dose (PRIME Study): A randomized, double-blind, plac	25
Near-infrared fluorescence imaging compared to standard sentinel lymph node detection with blue dye in patients with vulvar cancer – a randomized controlled trial	25
The role of semiquantitative evaluation of lympho-vascular space invasion in early stage cervical cancer patients	25
Candidate RNA biomarkers in biofluids for early diagnosis of ovarian cancer: A systematic review	25
Feasibility, acceptability and effects of multimodal pelvic floor physical therapy for gynecological cancer survivors suffering from painful sexual intercourse: A multicenter prospective interventiona	24
Impact of Obesity on Sentinel Lymph Node Mapping in Patients with apparent Early-Stage Endometrial Cancer: The ObeLyX study	24
Contemporary management of ovarian germ cell tumors and remaining controversies	24
Adapting and avoiding coping strategies for women with ovarian cancer during the COVID-19 pandemic	24
Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial	24
Tumor-infiltrating lymphocytes and POLE mutation in endometrial carcinoma	24
Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer	24
Prospective analysis of circulating metabolites and endometrial cancer risk	24
Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer	24
Racial and ethnic disparities in palliative care utilization among gynecological cancer patients	24
POLE mutation combined with microcystic, elongated and fragmented (MELF) pattern invasion in endometrial carcinomas might be associated with poor survival in Chinese women	24
A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary ini	23
Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer	23
Trends in HPV-dependent and HPV-independent vulvar cancers: The changing face of vulvar squamous cell carcinoma	23
Tumor-infiltrating lymphocytes predict survival outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy	23
Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer	23
Clear cell carcinoma of the endometrium	23
Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients	23
Wait-time for hysterectomy and survival of women with early-stage cervical cancer: A clinical implication during the coronavirus pandemic	23
The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes	23
Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group	23
Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies	23
Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?	23
Differences in cervical cancer screening and follow-up for black and white women in the United States	23
The ASTRO clinical practice guidelines in cervical cancer: Optimizing radiation therapy for improved outcomes	23
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis	22
The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis	22
Neuroendocrine tumors of the gynecologic tract update	22
Clinical impact of low-volume lymph node metastases in early-stage cervical cancer: A comprehensive meta-analysis	22
Effect of frailty on postoperative readmissions and cost of care for ovarian cancer	22
Clear cell endometrial carcinomas with mismatch repair deficiency have a favorable prognosis: A systematic review and meta-analysis	22
Adipocytokines and their relationship to endometrial cancer risk: A systematic review and meta-analysis	22
Diagnostic value of frozen section examination of sentinel lymph nodes in early-stage cervical cancer at the time of ultrastaging	22
Is routine omentectomy of grossly normal omentum helpful in surgery for ovarian cancer? A look at the tumor microenvironment and its clinical implications	22
Oncologic results of fertility sparing surgery of cervical cancer: An updated systematic review	21
A systematic review on the use of artificial intelligence in gynecologic imaging – Background, state of the art, and future directions	21
Global distribution, risk factors, and recent trends for cervical cancer: A worldwide country-level analysis	21
Clinical significance of homologous recombination deficiency score testing in endometrial Cancer	21

Reproductive and obstetric outcomes after abdominal radical trachelectomy (ART) for patients with early-stage cervical cancers in Fudan, China	21
Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis	21
OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab	21
Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States	21
Clinical and imaging findings in cervical cancer and their impact on FIGO and TNM staging – An analysis from the EMBRACE study	21
Risk of vulvar, vaginal and anal high-grade intraepithelial neoplasia and cancer according to cervical human papillomavirus (HPV) status: A population-based prospective cohort study	21
Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial	21
Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials	21
Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines	21
Angiogenesis in endometrial carcinoma: Therapies and biomarkers, current options, and future perspectives	21
Rural disparities in surgical care from gynecologic oncologists among Midwestern ovarian cancer patients	21
The impact of marital status on stage at diagnosis and survival of female patients with breast and gynecologic cancers: A meta-analysis	21
Using machine learning to create prognostic systems for endometrial cancer	21
Adherence to treatment guidelines as a major determinant of survival disparities between black and white patients with ovarian cancer	21
Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer	20
Ultra-radical upfront surgery does not improve survival in women with advanced epithelial ovarian cancer; a natural experiment in a complete population	20
Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases	20
Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis	20
Decreasing utilization of minimally invasive hysterectomy for cervical cancer in the United States	20
Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification	20
A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology	20
Frailty Index for prediction of surgical outcome in ovarian cancer: Results of a prospective study	20
The added value of sentinel node mapping in endometrial cancer	20
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer	20
Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 study	20
Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma	20
Simple conization and pelvic lymphadenectomy in early-stage cervical cancer: A retrospective analysis and review of the literature	20
Laparo-assisted vaginal radical hysterectomy as a safe option for Minimal Invasive Surgery in early stage cervical cancer: A systematic review and meta-analysis	20
Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation	20
Prospective cohort study of metabolic syndrome and endometrial cancer survival	20
Clinical needs for transgender men in the gynecologic oncology setting	20
Racial disparities in survival among women with endometrial cancer in an equal access system	20
Stereotactic body radiation therapy for oligometastatic gynecologic malignancies: A systematic review	20
Mutation profiling of uterine cervical cancer patients treated with definitive radiotherapy	19
A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study	19
The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers	19
When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer	19
PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer	19
Less guessing, more evidence in identifying patients least fit for cytoreductive surgery in advanced ovarian cancer: A triage algorithm to individualize surgical management	19
A population-based study of causes of death after endometrial cancer according to major risk factors	19
Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort	19
MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer	19
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer	19
Surgical training in gynecologic oncology: Past, present, future	19
Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer	19
The risk of developing squamous cell carcinoma in patients with anogenital lichen sclerosis: A systematic review	19
Prognostic value of systemic hemato-immunological indices in uterine cervical cancer: A systemic review, meta-analysis, and meta-regression of observational studies	19
Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial)	19
Promoting health equity in the era of COVID-19	19
Cervical conization before primary radical hysterectomy has a protective effect on disease recurrence in early cervical cancer: A two-center matched cohort study according to surgical approach	19
Variation in practice in endometrial cancer and potential for improved care and equity through molecular classification	19
Cost-effectiveness analysis comparing “PARP inhibitors-for-all” to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer	19
Mitigation and management strategies for ocular events associated with tisotumab vedotin	19
Minority participation in phase 1 gynecologic oncology clinical trials: Three decades of inequity	19
Diagnostic value of indocyanine green fluorescence guided sentinel lymph node biopsy in vulvar cancer: A systematic review	19
Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database	19
Incidence and risk factors for lower limb lymphedema associated with endometrial cancer: Results from a prospective, longitudinal cohort study.	18
Trends in the surgical management of malignant ovarian germcell tumors	18
Is the risk of substantial LVSI in stage I endometrial cancer similar to PORTEC in the North American population? – A single-institution study	18
A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer	18
Visceral obesity and muscle mass determined by CT scan and surgical outcome in patients with advanced ovarian cancer. A retrospective cohort study	18
Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancer	18
Comprehensive analysis of patient outcome after local recurrence of locally advanced cervical cancer treated with concomitant chemoradiation and image-guided adaptive brachytherapy	18
Genomic characterization of vulvar squamous cell carcinoma	18
Maintaining surgical care delivery during the COVID-19 pandemic: A comparative cohort study at a tertiary gynecological cancer centre	18
Homologous recombination repair mutation gene panels (excluding BRCA) are not predictive of maintenance olaparib plus bevacizumab efficacy in the first-line PAOLA-1/ENGOT-ov25 trial	18
Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience	18
Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement	18
Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape.	18
Crowdsourcing to measure financial toxicity in gynecologic oncology	18
Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II	18
Association between pelvic inflammatory disease and risk of ovarian cancer: An updated meta-analysis	18
Recurrence and survival after laparoscopy versus laparotomy without lymphadenectomy in early-stage endometrial cancer: Long-term outcomes of a randomised trial	18
Incidence trends of vulvar squamous cell carcinoma in Italy from 1990 to 2015	18
Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma	18
Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy	17
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial	17
Neoadjuvant chemotherapy followed by fertility sparing surgery in cervical cancers size 2–4 cm; emerging data and future perspectives	17
The next generation sequencing of cancer-related genes in small cell neuroendocrine carcinoma of the cervix	17
Knowledge of endometrial cancer risk factors in a general gynecologic population	17
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial	17
Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study (LBA 4)	17
An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275	17
Patterns of recurrence and survival in vulvar cancer: A nationwide population-based study	17
Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer	17
Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer	17
Feasibility of tumor testing for BRCA status in high-grade serous ovarian cancer using fresh-frozen tissue based approach	17
Age-related distribution of uncommon HPV genotypes in cervical intraepithelial neoplasia grade 3	17
Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect	17
Insomnia and its association with quality of life in women with ovarian cancer	17
Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer	17
Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival	17
Where you live matters: A National Cancer Database study of Medicaid expansion and endometrial cancer outcomes	17
Using rADioMIcs and machine learning with ultrasonography for the differential diagnosis of myometRiAL tumors (the ADMIRAL pilot study). Radiomics and differential diagnosis of myometrial tumors	16
Incidence of vulvar high-grade precancerous lesions and cancer in Denmark before and after introduction of HPV vaccination	16